Xbrane Biopharma AB (publ) (XBRANE.ST)
Xbrane Biopharma AB (publ)
Retzius vAeg 8
Solna 171 65
Sweden
46 8 55 90 56 00
https://www.xbrane.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 71
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Martin Amark | Chief Executive Officer | 3.28M | N/A | 1980 |
| Mr. Siavash Bashiri | COO, Head of Biosimilars & Deputy CEO | 1.79M | N/A | 1983 |
| Associate Prof. Jan-Willem De Gier | Co-Founder | N/A | N/A | N/A |
| Dr. Samuel Wagner Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/A | N/A | N/A |
| Ms. Anette Lindqvist | CFO & Head of Investor Relations | N/A | N/A | 1961 |
| Dr. David Vikström | Chief Technology Officer | N/A | N/A | 1977 |
| Ms. Dina Jurman | Head of Clinical Affairs | N/A | N/A | 1982 |
| Mr. Anders Wallström | Head of Manufacturing & Supply Chain | N/A | N/A | 1976 |
| Mr. Håkan Yildirim | Head of Intellectual Property | N/A | N/A | N/A |
Description
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis, Crohn's disease, and axial spondylitis; Xdivane, a nivolumab biosimilar candidate, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
Corporate Governance
Xbrane Biopharma AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
